12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
| 应用 | 稀释度 |
|---|---|
| ELISA | 0.305-5000 ng/ml |
| FCM | 1:20000 |
Cetuximab is a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR) which is present on the surface of some cancer cells. Cetuximab binds to the receptor, preventing epidermal growth factor (EGF) from binding to it and stimulating growth of the cancer cells. Cetuximab is used to treat squamous cell cancer of the head and neck. Cetuximab is commonly used alongside chemotherapy as a first line approach to cancer that has spread or is recurring. It is also used alongside radiation therapy in localized disease. Patients with metastatic colorectal cancer that expresses EGFR may be treated with cetuximab in combination with chemotherapy or cetuximab may be given as a single therapy to patients who have failed to respond to irinotecan- and oxaliplatin-based regimens.
Flow cytometric analysis of MCF7 (Human breast adenocarcinoma epithelial cell, left) / A431 (Human epidermoid carcinoma epithelial cell, right) labelling EGFR antibody at 1/20000 dilution (0.01 μg) / (Red) compared with a Human monoclonal IgG (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). Goat Anti - Human IgG Alexa Fluor® 647 was used as the secondary antibody. Negative control: MCF7
Immobilized human EGFR at 0.5 μg/ml (50μL/well) can bind to Cetuximab with a linear range of 0.305 ng/ml-5 μg/ml.
您现在的位置：